We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00670436
First Posted: May 1, 2008
Last Update Posted: June 10, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
B. Braun Melsungen AG
Information provided by (Responsible Party):
Jochen Wohrle, University of Ulm
  Purpose
The aim of the study is to assess the safety and efficacy of a Paclitaxel-eluting PTCA-balloon in combination with bare-metal stenting for treatment of chronic total occlusions in native coronary arteries with reference diameters between 2.5 mm and 4.0 mm.

Condition Intervention Phase
Coronary Artery Disease Chronic Total Occlusion Native Coronary Artery Device: paclitaxel eluting PTCA balloon catheter (SeQuent Please) Device: paclitaxel eluting Taxus stent (Boston Scientific) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions

Resource links provided by NLM:


Further study details as provided by Jochen Wohrle, University of Ulm:

Primary Outcome Measures:
  • Late loss [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • percent diameter stenosis [ Time Frame: 6 months ]
  • binary angiographic restenosis rate [ Time Frame: 6 months ]
  • late loss index [ Time Frame: 6 months ]
  • Target lumen revascularization [ Time Frame: 30 days, 6, 12, 24 months ]
  • target vessel revascularization [ Time Frame: 30 days, 6, 12, 24 months ]
  • major adverse cardiac events [ Time Frame: 30 days, 6, 12, 24 months ]

Enrollment: 48
Study Start Date: February 2008
Study Completion Date: March 2014
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A 1
paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
Device: paclitaxel eluting PTCA balloon catheter (SeQuent Please)
paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
Other Names:
  • SeQuent Please
  • paclitaxel eluting balloon
Active Comparator: A2
historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
Device: paclitaxel eluting Taxus stent (Boston Scientific)
paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • chronic total occlusion
  • Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1
  • occlusion in native coronary artery
  • indication for percutaneous coronary intervention based on symptoms, prognosis or evidence of ischemia
  • reference diameter 2.5 mm to 4.0 mm

Exclusion Criteria:

  • saphenous vein graft
  • bifurcation lesion with need to stent main and side branch
  • left main occlusion
  • de-novo stenosis (no occlusion)
  • restenosis
  • in-stent restenosis
  • contraindication for dual antiplatelet therapy with acetylsalicylic acid and clopidogrel for 6 months
  • coronary aneurysm at target lesion
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00670436


Locations
Germany
Klinikum Darmstadt
Darmstadt, Germany, 64283
University of Ulm
Ulm, Germany, 89081
Sponsors and Collaborators
University of Ulm
B. Braun Melsungen AG
Investigators
Principal Investigator: Jochen Wöhrle, MD; FESC University of Ulm, Ulm, Germany
  More Information

Publications:
Responsible Party: Jochen Wohrle, Prof. Dr. Jochen Wöhrle, University of Ulm
ClinicalTrials.gov Identifier: NCT00670436     History of Changes
Other Study ID Numbers: PEPCAD-CTO V 2.3
First Submitted: April 29, 2008
First Posted: May 1, 2008
Last Update Posted: June 10, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action